HANSOH PHARMA3692.HKValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 16, 2026, HANSOH PHARMA (3692.HK) trades at a P/E of 25.10x, P/B of 4.41x, P/S of 10.60x, and a dividend yield of 1.52%.
Longitudinal percentile comparison: P/E sits at the 22nd percentile over the trailing 10Y window (vs. 31st percentile over 3Y); P/B sits at the 44th percentile over the trailing 10Y window (vs. 50th percentile over 3Y); P/S sits at the 49th percentile over the trailing 10Y window (vs. 52nd percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 90th percentile within its industry and the 80th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 1.52%, ranking at the 88th percentile over the trailing 20Y window.
Notably, P/E and P/B aren't telling quite the same story, 22.6 points apart — worth checking the full percentile matrix on this page for the complete picture. The P/E percentile sits lower across the market than within its own industry — relatively cheaper next to the market as a whole. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. HANSOH PHARMA operates in the Pharmaceutical Chemistry sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: HKG: 3692 · SEHK: 3692 · 3692
Want the full picture on whether HANSOH PHARMA (3692.HK) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 25.10 | ||||||
| P/B (MRQ) | 4.41 | ||||||
| P/S (TTM) | 10.60 | ||||||
| Dividend Yield | 1.52% | ||||||
| Buyback + Div Yield | 1.52% |